HTF Market Intelligence released a new research report of 225 pages on title ‘Atherosclerosis – Pipeline Review, H1 2017’ with detailed analysis, forecast and strategies. The study covers key regions and important players such as Dybly AG, Esperion Therapeutics Inc, Forty Seven Inc etc.
Request a sample report @ https://www.htfmarketreport.com/sample-report/437117-atherosclerosis-pipeline-review
The latest Pharmaceutical and Healthcare disease pipeline guide Atherosclerosis – Pipeline Review, H1 2017, provides an overview of the Atherosclerosis (Cardiovascular) pipeline landscape.
Atherosclerosis (or arteriosclerotic vascular disease) is a condition where the arteries become narrowed and hardened due to an excessive build up of plaque around the artery wall. The disease disrupts the flow of blood around the body, posing serious cardiovascular complications. Symptoms of atherosclerosis are chest pain (angina), pain in the leg, arm, and anywhere else that an artery is blocked, shortness of breath, fatigue, confusion (if the blockage affects circulation to the brain) and muscle weakness in the legs from lack of circulation.
The Pharmaceutical and Healthcare latest pipeline guide Atherosclerosis – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Atherosclerosis (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Atherosclerosis (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Atherosclerosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 4, 5, 43 and 11 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 21 and 5 molecules, respectively.
Atherosclerosis (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from The proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Buy this report @ https://www.htfmarketreport.com/buy-now?format=1&report=437117
– The pipeline guide provides a snapshot of the global therapeutic landscape of Atherosclerosis (Cardiovascular).
– The pipeline guide reviews pipeline therapeutics for Atherosclerosis (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Atherosclerosis (Cardiovascular) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Atherosclerosis (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Atherosclerosis (Cardiovascular)
Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Atherosclerosis (Cardiovascular).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Atherosclerosis (Cardiovascular) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned in the Report
Annexin Pharmaceuticals AB
Arisaph Pharmaceuticals Inc
Athera Biotechnologies AB
Bristol-Myers Squibb Company
Cerenis Therapeutics Holding SA
Daiichi Sankyo Company Ltd
Esperion Therapeutics Inc
Forty Seven Inc
Jenrin Discovery Inc
Kang Stem Biotech Co Ltd
Kowa Company Ltd
Lead Discovery Center GmbH
LipimetiX Development Inc
Merck & Co Inc
Otsuka Holdings Co Ltd
Unity Biotechnology Inc
Vascular Biogenics Ltd
Vicore Pharma AB
Make an enquiry before buying this Report @ https://www.htfmarketreport.com/enquiry-before-buy/437117-atherosclerosis-pipeline-review
Table of Contents
Atherosclerosis – Overview 6
Atherosclerosis – Therapeutics Development 7
Atherosclerosis – Therapeutics Assessment 21
Atherosclerosis – Companies Involved in Therapeutics Development 33
Atherosclerosis – Drug Profiles 51
Atherosclerosis – Dormant Projects 192
Atherosclerosis – Discontinued Products 199
Atherosclerosis – Product Development Milestones 201
Appendix 215List of Tables
Number of Products under Development for Atherosclerosis, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017
View Detailed Table of Content @ https://www.htfmarketreport.com/reports/437117-atherosclerosis-pipeline-review
CRAIG FRANCIS (PR & Marketing Manager)
Ph: +1 (206) 317 1218